Overview

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m². Pharmacokinetic evaluation of belinostat 1,000 mg/m² and metabolites in the presence of warfarin 5 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Collaborator:
Onxeo
Treatments:
Belinostat
Warfarin